The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05173493

Enrollment

670

Registered

2021-12-30

Start date

2021-12-30

Completion date

2023-02-10

Last updated

2023-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Keywords

Helicobacter pylori, Re-eradication time, Remedial treatment

Brief summary

The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

Detailed description

Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer. At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment inpatients with Hp eradication failure.

Interventions

DRUGAmoxicillin,Furazolidone

Amoxicillin-Furazolidone-containing quadruple group

DRUGAmoxicillin,Levofloxacin

Amoxicillin-Levofloxacin-containing quadruple group

DRUGTetracycline,Furazolidone

Tetracycline-Furazolidone-containing quadruple group

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients aged 18-70 with H. pylori infection. * Patients with previous Helicobacter pylori eradication.

Exclusion criteria

* Patients treated with H2-receptor antagonist, PPI, bismuth and antibioticsin the previous 4 weeks. * Patients with gastrectomy, acute GI bleeding and advanced gastric cancer. * Patients with known or suspected allergy to study medications. * Currently pregnant or lactating. * Inability to provide informed consent and other situations that couldinterfere with the examination or therapeutic protocol.

Design outcomes

Primary

Measure	Time frame	Description
The most suitable re-eradication time	6 months	The most suitable re-eradication time（The unit is month） will be assessed by paired comparison method .

Secondary

Measure	Time frame	Description
Eradication rates in three groups	6months	Both intention to treat(ITT) and per-protocol(PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in three groups.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026